This means the FDA does not specifically review the safety, effectiveness, or quality of compounded medications before they are given to patients
CAGRISEMA is a dual-peptide research blend combining Cagrilintide (amylin analog) and Semaglutide (GLP-1 receptor agonist), widely studied for its role in appetite regulation signaling, metabolic efficiency pathways, and glucose homeostasis mechanisms
Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
The winner may be the company that best balances efficacy, tolerability, supply, pricing, payer coverage, and patient persistence